
    
      This is a prospective, randomized, multicenter, open-label study. After more than 24 weeks NA
      treatment, HBeAg positive CHB patients who achieved HBV DNA<1000copies/ml but HBeAb negative,
      will be randomized (1:1) into 2 study arms as follows:

      Arm A: Peginterferon alfa-2a 180Î¼g /wk plus NA 1piece qd for 48 weeks Arm B:NA 1 piece qd for
      48 weeks

      The primary endpoint: HBeAg seroconversion at week 48
    
  